Figure 2. CD8+ Teffs localize to sites of vaccination with noncognate antigen.
(A) Mice bearing 7-day-old, s.c. B16 tumors received 6-day-cultured, gp100-specific pmel-1 or OVA-specific OT-1 Teffs i.v., followed by vaccination with hgp100/IFA (right flank, s.c.) or OVA/IFA (right flank, s.c.). v-effLuc–transduced OT-1 T cells (left panel) and v-effLuc–transduced pmel-1 T cells (right panel) were visualized by whole-mouse imaging 4 days after vaccination. Color bars represent mean ± SEM photons/second (n = 5, *P < 0.05) determined by 1-way ANOVA with a post hoc test. Statistical differences between the 2 groups were determined by the unpaired 2-tailed t test. (B–E) Mice bearing 3-day-old, s.c. B16 melanoma received naive CD90.1+ pmel-1 T cells, early anti–CTLA-4 therapy, and vaccination with control/IFA or hgp100/IFA. Tumor and vaccination sites were harvested 9 days after vaccination. (B) Non–pmel-1 Teffs (CD44hiCD11ahiCD8+CD90.1–). (C) TRP-2–specific Teffs (TRP-2181–188 pentamer–specific Teffs). (D) pmel-1 Teffs (CD44hiCD11ahiCD8+CD90.1+). Absolute number counts were adjusted per tissue weight resection from tumor and vaccination sites. Data (B–D) represent mean ± SEM of 3 independent experiments (n = 5, *P < 0.05 unpaired 2-tailed t test). (E) Experimental scheme (top) showing Kaplan-Meier survival curve data pooled from 3 independent experiments (n = 5 mice per group, bottom). *P < 0.05, log-rank test.